211 related articles for article (PubMed ID: 36656341)
21. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
[TBL] [Abstract][Full Text] [Related]
22. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
23. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
24. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.
Makanga DR; Jullien M; David G; Legrand N; Willem C; Dubreuil L; Walencik A; Touzeau C; Gastinne T; Tessoulin B; Le Gouill S; Mahé B; Gagne K; Chevallier P; Clemenceau B; Retière C
Oncoimmunology; 2021 Jun; 10(1):1936392. PubMed ID: 34178429
[TBL] [Abstract][Full Text] [Related]
25. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity.
Parsons MS; Wren L; Isitman G; Navis M; Stratov I; Bernard NF; Kent SJ
J Virol; 2012 Apr; 86(8):4488-95. PubMed ID: 22345455
[TBL] [Abstract][Full Text] [Related]
26. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
Cho H; Kim KH; Lee H; Kim CG; Chung H; Choi YS; Park SH; Cheong JW; Min YH; Shin EC; Kim JS
Clin Cancer Res; 2021 May; 27(10):2947-2958. PubMed ID: 33602683
[TBL] [Abstract][Full Text] [Related]
27. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
29. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
Sun H; Martin TG; Marra J; Kong D; Keats J; Macé S; Chiron M; Wolf JL; Venstrom JM; Rajalingam R
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272304
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
31. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.
Bonanni V; Antonangeli F; Santoni A; Bernardini G
J Immunother Cancer; 2019 Nov; 7(1):290. PubMed ID: 31699153
[TBL] [Abstract][Full Text] [Related]
32. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
[TBL] [Abstract][Full Text] [Related]
33. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells.
Wren L; Parsons MS; Isitman G; Center RJ; Kelleher AD; Stratov I; Bernard NF; Kent SJ
PLoS One; 2012; 7(6):e38580. PubMed ID: 22701674
[TBL] [Abstract][Full Text] [Related]
34. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
35. Deficient IL-2 Produced by Activated CD56
Xie Z; Zheng J; Wang Y; Li D; Maermaer T; Li Y; Tu J; Xu Q; Liang H; Cai W; Shen T
Front Immunol; 2019; 10():1647. PubMed ID: 31379845
[No Abstract] [Full Text] [Related]
36. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
[TBL] [Abstract][Full Text] [Related]
38. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
Gooneratne SL; Center RJ; Kent SJ; Parsons MS
Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
[TBL] [Abstract][Full Text] [Related]
39. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
40. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]